Mar 7 |
Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024
|
Mar 6 |
Cyclacel Pharmaceuticals receives $2.9M R&D tax credit
|
Mar 6 |
Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit
|
Feb 20 |
Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference
|
Jan 30 |
Cyclacel Pharmaceuticals stock slumps on termination of chief medical officer
|
Jan 30 |
Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer
|
Jan 19 |
Cyclacel Pharmaceuticals files to sell 411K shares of common stock
|
Jan 8 |
Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
|
Jan 8 |
CYCC regains compliance with Nasdaq
|
Jan 8 |
Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement
|